{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:52:20Z","timestamp":1770508340925,"version":"3.49.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Clear and updated endpoints are required to measure outcomes of a disease course and\/or a therapeutic intervention. The aim of this review is to identify a reliable \u2018time-in-range\u2019 endpoint of clinical outcomes in ocular conditions, with a particular focus on exudative diseases involving the posterior pole of the eye, and to explore possible applications of this endpoint. A PubMed search was carried out pertaining to: \u2018time-in-range\u2019, \u2018clinical-outcome\u2019, \u2018clinical-endpoint\u2019, \u2018clinical trial\u2019, \u2018metrics\u2019, \u2018retina\u2019, \u2018retinopathy\u2019, \u2018macular-oedema\u2019, \u2018maculopathy\u2019, \u2018ophthalmology\u2019, \u2018visual-function\u2019, \u2018visual acuity end-point\u2019 and \u2018OCT\u2019. The results showed that both functional and morphological endpoints have been used in the evaluation of retinal diseases. At present, the most widely accepted and clinically meaningful marker of ocular disease is \u2018mean change\u2019 in best corrected visual acuity (BCVA). While comparisons to baseline at various timepoints are commonly recommended to evaluate statistical and clinically relevant differences, few metrics capture the disease course continuously over time. In other medical fields, \u2018time-in-range\u2019 has been introduced to provide more complete information on the fluctuations characterising the course of a disease. The application of \u2018time-in-range\u2019 on BCVA in exudative diseases involving the posterior pole seems feasible, reliable and applicable in clinical practice. BCVA \u2018time-in-range\u2019 offers a useful and practical endpoint in retinal diseases, evaluating both visual function at the end of an observation\/treatment and fluctuations in disease over time. It may also be applied to other clinical and morphological endpoints in ocular diseases, including macular thickness. This review presents a hypothesis-generating framework proposing \u2018time-in-range\u2019 as a supplementary metric, pending prospective validation.<\/jats:p>","DOI":"10.1038\/s41433-025-04112-6","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T19:04:01Z","timestamp":1765911841000},"page":"310-318","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and standardisation of \u2018time-in-range\u2019 measurement for clinical endpoints in retinal diseases"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1749-2737","authenticated-orcid":false,"given":"Luisa","family":"Frizziero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Barratt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3358-3516","authenticated-orcid":false,"given":"Chui Ming Gemmy","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrii","family":"Korol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3132-6233","authenticated-orcid":false,"given":"Edoardo","family":"Midena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6126-6476","authenticated-orcid":false,"given":"James","family":"Talks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miltiadis","family":"Tsilimbaris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1813-0017","authenticated-orcid":false,"given":"Igor","family":"Kozak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"4112_CR1","doi-asserted-by":"crossref","unstructured":"Schmetterer L, Scholl H, Garh\u00f6fer G, Janeschitz-Kriegl L, Corvi F, Sadda SR, et al. Endpoints for clinical trials in ophthalmology. Prog Retin Eye Res. 2023;97:101160.","DOI":"10.1016\/j.preteyeres.2022.101160"},{"key":"4112_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2019.100486","volume":"16","author":"C McLeod","year":"2019","unstructured":"McLeod C, Norman R, Litton E, Saville BR, Webb S, Snelling TL. Choosing primary endpoints for clinical trials of health care interventions. Contemp Clin Trials Commun. 2019;16:100486.","journal-title":"Contemp Clin Trials Commun"},{"key":"4112_CR3","unstructured":"US Food and Drug Administration. 2011 Meeting Materials, Cellular, Tissue and Gene Therapies Advisory Committee. (2011). https:\/\/wayback.archive-it.org\/7993\/20170111173922\/http:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/BloodVaccinesandOtherBiologics\/CellularTissueandGeneTherapiesAdvisoryCommittee\/ucm249846.htm."},{"key":"4112_CR4","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1038\/s41433-023-02507-x","volume":"37","author":"I Kozak","year":"2023","unstructured":"Kozak I, Pearce I, Cheung CMG, Machewitz T, Lambrou GN, Molina D, et al. Visual acuity time in range: a novel concept to describe consistency in treatment response in diabetic macular oedema. Eye. 2023;37:3367\u201375.","journal-title":"Eye"},{"key":"4112_CR5","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jamaophthalmol.2018.6786","volume":"137","author":"SB Bressler","year":"2019","unstructured":"Bressler SB, Odia I, Maguire MG, Dhoot DS, Glassman AR, Jampol LM, et al. Factors associated with visual acuity and central subfield thickness changes when treating diabetic macular edema with anti-vascular endothelial growth factor therapy: an exploratory analysis of the Protocol T randomized clinical trial. JAMA Ophthalmol. 2019;137:382\u201390.","journal-title":"JAMA Ophthalmol"},{"key":"4112_CR6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2337\/ds20-0097","volume":"34","author":"JG Timmons","year":"2021","unstructured":"Timmons JG, Boyle JG, Petrie JR. Time in range as a research outcome measure. Diabetes Spectr. 2021;34:133\u20138.","journal-title":"Diabetes Spectr"},{"key":"4112_CR7","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.2337\/dc18-1131","volume":"41","author":"J Lu","year":"2018","unstructured":"Lu J, Ma X, Zhou J, Zhang L, Mo Y, Ying L, et al. Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes. Diabetes Care. 2018;41:2370\u20136.","journal-title":"Diabetes Care"},{"key":"4112_CR8","doi-asserted-by":"publisher","first-page":"968","DOI":"10.2337\/diab.44.8.968","volume":"44","author":"The Diabetes Control and Complications Trial Research Group","year":"1995","unstructured":"The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes. 1995;44:968\u201383.","journal-title":"Diabetes"},{"key":"4112_CR9","doi-asserted-by":"publisher","first-page":"400","DOI":"10.2337\/dc18-1444","volume":"42","author":"RW Beck","year":"2019","unstructured":"Beck RW, Bergenstal RM, Riddlesworth TD, Kollman C, Li Z, Brown AS, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care. 2019;42:400\u20135.","journal-title":"Diabetes Care"},{"key":"4112_CR10","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2337\/dc20-1862","volume":"44","author":"J Lu","year":"2021","unstructured":"Lu J, Wang C, Shen Y, Chen L, Zhang L, Cai J, et al. Time in range in relation to all-cause and cardiovascular mortality in patients with type 2 diabetes: a prospective cohort study. Diabetes Care. 2021;44:549\u201355.","journal-title":"Diabetes Care"},{"key":"4112_CR11","first-page":"316","volume":"12","author":"S Al Sifri","year":"2021","unstructured":"Al Sifri S, Alshaikh A, Bin-Abbas B, Sheshah E, Al Sabaan F, Al-Dawish M, et al. The use of standardized reporting and time-in-range in the management of diabetes: a consensus report. Int J Clin Exp Med. 2021;12:316\u201327.","journal-title":"Int J Clin Exp Med"},{"key":"4112_CR12","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","volume":"154","author":"GYH Lip","year":"2018","unstructured":"Lip GYH, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, et al. Antithrombotic therapy for atrial fibrillation:\u00a0CHEST guideline and expert panel report. Chest. 2018;154:1121\u2013201.","journal-title":"Chest"},{"key":"4112_CR13","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1089\/aid.2009.0263","volume":"26","author":"A Audig\u00e9","year":"2010","unstructured":"Audig\u00e9 A, Taff\u00e9 P, Rickenbach M, Battegay M, Vernazza P, Nadal D, et al. Low postseroconversion CD4 count and rapid decrease of CD4 density identify HIV+ fast progressors. AIDS Res Hum Retroviruses. 2010;26:997\u20131005.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"4112_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13098-020-00529-z","volume":"12","author":"MAL Gabbay","year":"2020","unstructured":"Gabbay MAL, Rodacki M, Calliari LE, Vianna AGD, Krakauer M, Pinto MS, et al. Time in range: a new parameter to evaluate blood glucose control in patients with diabetes. Diabetol Metab Syndr. 2020;12:22.","journal-title":"Diabetol Metab Syndr"},{"key":"4112_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s40662-022-00286-2","volume":"9","author":"R Han","year":"2022","unstructured":"Han R, Gong R, Liu W, Xu G. Optical coherence tomography angiography metrics in different stages of diabetic macular edema. Eye Vis. 2022;9:14.","journal-title":"Eye Vis"},{"key":"4112_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1167\/tvst.11.3.27","volume":"11","author":"M Sa\u00dfmannshausen","year":"2022","unstructured":"Sa\u00dfmannshausen M, Thiele S, Behning C, Pfau M, Schmid M, Leal S, et al. Intersession repeatability of structural biomarkers in early and intermediate age-related macular degeneration: a MACUSTAR study report. Transl Vis Sci Technol. 2022;11:27.","journal-title":"Transl Vis Sci Technol"},{"key":"4112_CR17","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41433-021-01488-z","volume":"36","author":"MK Grewal","year":"2022","unstructured":"Grewal MK, Chandra S, Gurudas S, Rasheed R, Sen P, Menon D, et al. Functional clinical endpoints and their correlations in eyes with AMD with and without subretinal drusenoid deposits \u2013 a pilot study. Eye. 2022;36:398\u2013406.","journal-title":"Eye"},{"key":"4112_CR18","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1159\/000515148","volume":"244","author":"Y Yang","year":"2021","unstructured":"Yang Y, Dunbar H. Clinical perspectives and trends: microperimetry as a trial endpoint in retinal disease. Ophthalmologica. 2021;244:418\u201350.","journal-title":"Ophthalmologica"},{"key":"4112_CR19","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/S0161-6420(13)38011-7","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1991","unstructured":"Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology. 1991;98:766\u201385.","journal-title":"Ophthalmology"},{"key":"4112_CR20","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1159\/000515406","volume":"244","author":"CMG Cheung","year":"2021","unstructured":"Cheung CMG, Pearce E, Fenner B, Sen P, Chong V, Sivaprasad S. Looking ahead: visual and anatomical endpoints in future trials of diabetic macular ischemia. Ophthalmologica. 2021;244:451\u201364.","journal-title":"Ophthalmologica"},{"key":"4112_CR21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1167\/iovs.07-1132","volume":"49","author":"KG Csaky","year":"2008","unstructured":"Csaky KG, Richman EA, Ferris FL III. Report from the NEI\/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci. 2008;49:479\u201389.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4112_CR22","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00417-023-06272-1","volume":"262","author":"HA R\u00edos","year":"2024","unstructured":"R\u00edos HA, L\u00f6vestam-Adrian M, Plainis S, Tsilimbaris M, Joussen AM, Keegan D, et al. Additional measures of macular function beyond visual acuity. Graefes Arch Clin Exp Ophthalmol. 2024;262:1723\u201336.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4112_CR23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ajo.2018.02.012","volume":"189","author":"KJ Cocce","year":"2018","unstructured":"Cocce KJ, Stinnett SS, Luhmann UFO, Vajzovic L, Horne A, Schuman SG, et al. Visual function metrics in early and intermediate dry age-related macular degeneration for use as clinical trial endpoints. Am J Ophthalmol. 2018;189:127\u201338.","journal-title":"Am J Ophthalmol"},{"key":"4112_CR24","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2147\/OPTH.S158268","volume":"12","author":"DR Nixon","year":"2018","unstructured":"Nixon DR, Flinn NAP. Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab. Clin Ophthalmol. 2018;12:191\u20137.","journal-title":"Clin Ophthalmol"},{"key":"4112_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-31109-x","volume":"8","author":"CMG Cheung","year":"2018","unstructured":"Cheung CMG, Shi Y, Tham YC, Sabanayagam C, Neelam K, Wang JJ, et al. Correlation of color fundus photograph grading with risks of early age-related macular degeneration by using automated OCT-derived drusen measurements. Sci Rep. 2018;8:12937.","journal-title":"Sci Rep"},{"key":"4112_CR26","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1177\/1120672121990624","volume":"31","author":"MC Puell","year":"2021","unstructured":"Puell MC, Contreras I, Pinilla I, Escobar JJ, Soler-Garc\u00eda A, Blasco AJ, et al. Beyond visual acuity: patient-relevant assessment measures of visual function in retinal diseases. Eur J Ophthalmol. 2021;31:3149\u201356.","journal-title":"Eur J Ophthalmol"},{"key":"4112_CR27","unstructured":"The Vision Academy. Additional Measures of Macular Function Beyond Visual Acuity. (2023). https:\/\/www.visionacademy.org\/media\/3026\/download."},{"key":"4112_CR28","doi-asserted-by":"publisher","first-page":"8435603","DOI":"10.1155\/2022\/8435603","volume":"2022","author":"Q Xu","year":"2022","unstructured":"Xu Q, Gong C, Qiao L, Feng R, Liu H, Liu Y, et al. Aqueous level of ANGPTL4 correlates with the OCTA metrics of diabetic macular edema in NPDR. J Diabetes Res. 2022;2022:8435603.","journal-title":"J Diabetes Res"},{"key":"4112_CR29","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1007\/s00417-019-04471-3","volume":"257","author":"Y Hu","year":"2019","unstructured":"Hu Y, Wu Q, Liu B, Cao D, Dong X, Zhang L, et al. Comparison of clinical outcomes of different components of diabetic macular edema on optical coherence tomography. Graefes Arch Clin Exp Ophthalmol. 2019;257:2613\u201321.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4112_CR30","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/1089043","volume":"2018","author":"L Rangaraju","year":"2018","unstructured":"Rangaraju L, Jiang X, McAnany JJ, Tan MR, Wanek J, Blair NP, et al. Association between visual acuity and retinal layer metrics in diabetics with and without macular edema. J Ophthalmol. 2018;2018:1089043.","journal-title":"J Ophthalmol"},{"key":"4112_CR31","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.3390\/jcm10112296","volume":"10","author":"IP Marques","year":"2021","unstructured":"Marques IP, Kubach S, Santos T, Mendes L, Madeira MH, de Sisternes L, et al. Optical coherence tomography angiography metrics monitor severity progression of diabetic retinopathy \u2013 3-year longitudinal study. J Clin Med. 2021;10:2296.","journal-title":"J Clin Med"},{"key":"4112_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02767-0","volume":"7","author":"FY Tang","year":"2017","unstructured":"Tang FY, Ng DS, Lam A, Luk F, Wong R, Chan C, et al. Determinants of quantitative optical coherence tomography angiography metrics in patients with diabetes. Sci Rep. 2017;7:2575.","journal-title":"Sci Rep"},{"key":"4112_CR33","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ajo.2021.09.002","volume":"235","author":"E Borrelli","year":"2022","unstructured":"Borrelli E, Grosso D, Barresi C, Lari G, Sacconi R, Senni C, et al. Long-term visual outcomes and morphologic biomarkers of vision loss in eyes with diabetic macular edema treated with anti-VEGF therapy. Am J Ophthalmol. 2022;235:80\u20139.","journal-title":"Am J Ophthalmol"},{"key":"4112_CR34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00417-011-1774-x","volume":"250","author":"HJ Shin","year":"2012","unstructured":"Shin HJ, Lee SH, Chung H, Kim HC. Association between photoreceptor integrity and visual outcome in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2012;250:61\u201370.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4112_CR35","doi-asserted-by":"publisher","first-page":"100628","DOI":"10.1016\/j.xops.2024.100628","volume":"5","author":"JP Ehlers","year":"2024","unstructured":"Ehlers JP, Hu A, Boyer D, Cousins SW, Waheed NK, Rosenfeld PJ, et al. ReCLAIM-2: a randomized phase II clinical trial evaluating elamipretide in age-related macular degeneration, geographic atrophy growth, visual function, and ellipsoid zone preservation. Ophthalmol Sci. 2024;5:100628.","journal-title":"Ophthalmol Sci"},{"key":"4112_CR36","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41433-023-02637-2","volume":"38","author":"R Khoramnia","year":"2024","unstructured":"Khoramnia R, Nguyen QD, Kertes PJ, Sararols Ramsay L, Vujosevic S, Anderesi M, et al. Exploring the role of retinal fluid as a biomarker for the management of diabetic macular oedema. Eye. 2024;38:54\u201360.","journal-title":"Eye"},{"key":"4112_CR37","doi-asserted-by":"publisher","first-page":"3976","DOI":"10.3390\/jcm12123976","volume":"12","author":"P Marolo","year":"2023","unstructured":"Marolo P, Borrelli E, Gelormini F, Boscia G, Parisi G, Fallico M, et al. Retinal thickness deviation: a new OCT parameter for assessing diabetic macular edema. J Clin Med. 2023;12:3976.","journal-title":"J Clin Med"},{"key":"4112_CR38","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s40123-024-00925-y","volume":"13","author":"G Panozzo","year":"2024","unstructured":"Panozzo G, Cicinelli MV, Dalla Mura G, Giannarelli D, Vadal\u00e0 M, Bonfiglio V, et al. Enhancing diabetic macular edema treatment outcomes: exploring the ESASO classification and structural OCT biomarkers. Ophthalmol Ther. 2024;13:1383\u201398.","journal-title":"Ophthalmol Ther"},{"key":"4112_CR39","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1007\/s00417-022-05697-4","volume":"260","author":"SZ Gu","year":"2022","unstructured":"Gu SZ, Nanegrungsunk O, Bressler SB, Du W, Amer F, Moini H, et al. Correlation between change in central subfield thickness and change in visual acuity in macular edema due to retinal vein occlusion: post hoc analysis of COPERNICUS, GALILEO, and VIBRANT. Graefes Arch Clin Exp Ophthalmol. 2022;260:3799\u2013807.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4112_CR40","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ajo.2021.11.020","volume":"238","author":"O Nanegrungsunk","year":"2022","unstructured":"Nanegrungsunk O, Gu SZ, Bressler SB, Du W, Amer F, Moini H, et al. Correlation of change in central subfield thickness and change in visual acuity in neovascular AMD: post hoc analysis of VIEW 1 and 2. Am J Ophthalmol. 2022;238:97\u2013102.","journal-title":"Am J Ophthalmol"},{"key":"4112_CR41","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ajo.2021.06.030","volume":"232","author":"MR Starr","year":"2021","unstructured":"Starr MR, Salabati M, Mahmoudzadeh R, Patel LG, Ammar MJ, Hsu J, et al. Fluctuations in central subfield thickness associated with worse visual outcomes in patients with diabetic macular edema in clinical trial setting. Am J Ophthalmol. 2021;232:90\u20137.","journal-title":"Am J Ophthalmol"},{"key":"4112_CR42","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1001\/jamaophthalmol.2018.4516","volume":"137","author":"U Schmidt-Erfurth","year":"2019","unstructured":"Schmidt-Erfurth U, Michl M. Disorganization of retinal inner layers and the importance of setting boundaries. JAMA Ophthalmol. 2019;137:46\u20137.","journal-title":"JAMA Ophthalmol"},{"key":"4112_CR43","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/bjo-2024-326843","volume":"109","author":"L Danieli","year":"2025","unstructured":"Danieli L, Midena G, Frizziero L, Midena E. Disorganisation of inner retinal layers in diabetic macular oedema: is it time to standardise this OCT biomarker? Br J Ophthalmol. 2025;109:840\u20132.","journal-title":"Br J Ophthalmol"},{"key":"4112_CR44","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1001\/jamaophthalmol.2020.3001","volume":"138","author":"RN Evans","year":"2020","unstructured":"Evans RN, Reeves BC, Maguire MG, Martin DF, Muldrew A, Peto T, et al. Associations of variation in retinal thickness with visual acuity and anatomic outcomes in eyes with neovascular age-related macular degeneration lesions treated with anti-vascular endothelial growth factor agents. JAMA Ophthalmol. 2020;138:1043\u201351.","journal-title":"JAMA Ophthalmol"},{"key":"4112_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2022.100226","volume":"3","author":"A Torjani","year":"2023","unstructured":"Torjani A, Mahmoudzadeh R, Salabati M, Cai L, Hsu J, Garg S, et al. Factors associated with fluctuations in central subfield thickness in patients with diabetic macular edema using Diabetic Retinopathy Clinical Research Protocols T and V. Ophthalmol Sci. 2023;3:100226.","journal-title":"Ophthalmol Sci"},{"key":"4112_CR46","doi-asserted-by":"crossref","unstructured":"Kozak I, Do DV, Lai H, Ogidigben MJ, L\u00f3pez FJ. Time-in-range analysis of responses after intravitreal dexamethasone therapy in eyes with diabetic macular edema. Ophthalmol Sci. 2025;5:100833.","DOI":"10.1016\/j.xops.2025.100833"},{"key":"4112_CR47","unstructured":"Panjwani M, Kozak I, Holmes JM. Range for visual acuity and central subfield thickness as alternative outcome measures in clinical trials. Poster for the ARVO Annual Meeting. ARVO Annual Meeting, Salt Lake City, UT, USA, May 4\u20138, 2025."},{"key":"4112_CR48","doi-asserted-by":"publisher","first-page":"ix","DOI":"10.1016\/j.ajo.2023.08.013","volume":"256","author":"I Kozak","year":"2023","unstructured":"Kozak I, Stewart MW. The \u201ctime in range\u201d concept in ophthalmology. Am J Ophthalmol. 2023;256:ix\u2013x.","journal-title":"Am J Ophthalmol"},{"key":"4112_CR49","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1001\/jama.2019.5790","volume":"321","author":"CW Baker","year":"2019","unstructured":"Baker CW, Glassman AR, Beaulieu WT, Antoszyk AN, Browning DJ, Chalam KV, et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA. 2019;321:1880\u201394.","journal-title":"JAMA"},{"key":"4112_CR50","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","volume":"372","author":"Diabetic Retinopathy Clinical Resea","year":"2015","unstructured":"Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193\u2013203.","journal-title":"N Engl J Med"},{"key":"4112_CR51","first-page":"938","volume":"12","author":"PG Steinkuller","year":"2010","unstructured":"Steinkuller PG. Legal vision requirements for drivers in the United States. Virtual Mentor. 2010;12:938\u201340.","journal-title":"Virtual Mentor"},{"key":"4112_CR52","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1007\/s00125-024-06151-2","volume":"67","author":"SS Isaksson","year":"2024","unstructured":"Isaksson SS, Imberg H, Hirsch IB, Schwarcz E, Hellman J, Wijkman M, et al. Discordance between mean glucose and time in range in relation to HbA1c in individuals with type 1 diabetes: results from the GOLD and SILVER trials. Diabetologia. 2024;67:1517\u201326.","journal-title":"Diabetologia"},{"key":"4112_CR53","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1111\/dom.14504","volume":"23","author":"RM Goldenberg","year":"2021","unstructured":"Goldenberg RM, Aroda VR, Billings LK, Christiansen ASL, Meller Donatsky A, Parvaresh Rizi E, et al. Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia. Diabetes Obes Metab. 2021;23:2572\u201381.","journal-title":"Diabetes Obes Metab"},{"key":"4112_CR54","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s13300-020-00781-6","volume":"11","author":"T Battelino","year":"2020","unstructured":"Battelino T, Bosnyak Z, Danne T, Mukherjee B, Edelman S, Pilorget V, et al. InRange: comparison of the second-generation basal insulin analogues glargine 300 U\/mL and degludec 100 U\/mL in persons with type 1 diabetes using continuous glucose monitoring\u2014study design. Diabetes Ther. 2020;11:1017\u201327.","journal-title":"Diabetes Ther"},{"key":"4112_CR55","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1159\/000513591","volume":"244","author":"JH Terheyden","year":"2021","unstructured":"Terheyden JH, Schmitz-Valckenberg S, Crabb DP, Dunbar H, Luhmann UFO, Behning C, et al. Use of composite end points in early and intermediate age-related macular degeneration clinical trials: state-of-the-art and future directions. Ophthalmologica. 2021;244:387\u201395.","journal-title":"Ophthalmologica"},{"key":"4112_CR56","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1001\/jamaophthalmol.2021.5270","volume":"140","author":"D Zur","year":"2022","unstructured":"Zur D, Loewenstein A. Development in smartphone technologies and the advancement of home vision monitoring. JAMA Ophthalmol. 2022;140:161.","journal-title":"JAMA Ophthalmol"},{"key":"4112_CR57","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S0161-6420(93)31551-4","volume":"100","author":"JT Wilensky","year":"1993","unstructured":"Wilensky JT, Gieser DK, Dietsche ML, Mori MT, Zeimer R. Individual variability in the diurnal intraocular pressure curve. Ophthalmology. 1993;100:940\u20134.","journal-title":"Ophthalmology"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04112-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04112-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04112-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T22:04:56Z","timestamp":1770415496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04112-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4112"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-04112-6","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the acknowledgement section: it should read \u201cIPG Health Company\u201d instead of \u201cIG \u2026\u201d In affiliation 7 the extra-long dash has been updated to an en dash.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer. Financial arrangements of the authors with companies whose products may be related to the present report are declared below: LF: No financial interest related to the topic of this manuscript. JB: No financial interest related to the topic of this manuscript. CMGC: No financial interest related to the topic of this manuscript. Has received consultancy fees from Astellas, Bayer, Boehringer Ingelheim, Roche and Zeiss, has conducted research for Bayer, Boehringer Ingelheim, Novartis and Roche, and has received speaker fees from Bayer, Roche and Zeiss. Member of the\n                      Eye\n                      editorial board. AK: No financial interest related to the topic of this manuscript. Has received consultancy fees from Bayer, CheckEye, Novartis, Roche and Th\u00e9a, has received travel fees from Bayer, CheckEye and Th\u00e9a, has conducted research for Bayer, and is an advisor for CheckEye. EM: No financial interest related to the topic of this manuscript. JT: No financial interest related to the topic of this manuscript. Has conducted research for Alexion, Bayer, Boehringer Ingelheim, Janssen and Roche, and has received travel and consultancy fees from Bayer and Roche. MT: No financial interest related to the topic of this manuscript. Has conducted research for Alcon and Johnson & Johnson, and has received travel and consultancy fees from AbbVie, Bayer, Roche and Th\u00e9a. IP: No financial interest related to the topic of this manuscript. Has received consultancy fees from Apellis, Astellas, Bayer, Boehringer Ingelheim, Novartis and Roche, and has received speaker fees from Bayer, Roche and Novartis. IK: No financial interest related to the topic of this manuscript. Has conducted research for, and received consultancy fees from, AbbVie, Bayer, Novartis and Roche.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}